CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 438 enrolled
Drug / intervention
insulin degludec/liraglutide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01676116
NCT01676116Phase 3Completed
CompareCT.gov

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy (DUAL™ III -GLP-1 Switch)

Novo Nordisk A/S·interventional·Posted Aug 30, 2012·Updated Jan 3, 2019

In Brief

A Phase 3 clinical trial evaluating insulin degludec/liraglutide, liraglutide, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 438 participants across 109 sites in 5 countries.

Detailed Summary

This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of the trial is to investigate the efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes inadequately controlled on glucagon-like peptide-1 (GLP-1) receptor agonist and OAD therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesAustralia, France, Hungary, Slovakia, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 30, 2012
Enrollment StartAug 29, 2012
Primary CompletionMar 11, 2014
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 13.8 years ago

Interventions

insulin degludec/liraglutidedrug

Injected subcutaneously (under the skin) once daily. Dose individually adjusted. Subjects will continue their pre-trial OAD treatment without changing the frequency or dose throughout the trial.

liraglutidedrug

Subjects will continue on their pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.

exenatidedrug

Subjects will continue on their pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.